Outcomes | Anticipated absolute effects (95% CI) | Relative effect (95% CI) | № of (studies) | Certainty of the evidence (GRADE) | Comments | |
---|---|---|---|---|---|---|
Risk with placebo | Risk with galcanezumab | |||||
Reduction in migraine days follow up: 6 months | The mean reduction in migraine days was −2.8 days | The mean reduction in migraine days in the intervention group was 1.8 days fewer (2.3 fewer to 1.2 fewer) | – | 633 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with galcanezumab 240 mg results in reduction in migraine days compared with placebo. |
Reduction in use of acute attack medication follow up: 6 months | The mean reduction in use of acute attack medication was −2.2 days | The mean reduction in use of acute attack medication in the intervention group was 1.6 days fewer (2.1 fewer to 1.1 fewer) | – | 633 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with galcanezumab 240 mg results in reduction in use of attack medication compared with placebo. |
Improvement in functional MSQ RFR score follow up: 6 months | The mean improvement in functional MSQ RFR score was 24.7 points | The mean improvement in functional MSQ RFR score in the intervention group was 7.4 points higher (4.8 higher to 10 higher) | – | 561 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with galcanezumab 240 mg results in improvement in functional MSQ RFR score compared with placebo. |
At least 50% reduction in days of migraine follow up: 6 months | 386 per 1000 | 609 per 1000 (128 to 288) | RR 2.1508 (1.4247 to 3.2469) | 633 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with galcanezumab 240 mg results in at least 50% reduction of days of migraine compared with placebo. |
Serious adverse events follow up: 6 months | 12 per 1000 | 2 per 1000 (0 to 39) | RR 0.1633 (0.0091 to 2.9414) | 652 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with galcanezumab 240 mg results in a small possibly unimportant effect in serious adverse events occurrence compared with placebo. |
Mortality follow up: 6 months | 0 per 1000 | 0 per 1000 (0 to 0) | not estimable | 652 (1 RCT) | No deaths occurred during the double-blind treatment phase of the trial. |